Vapotherm, Inc., announced first quarter 2024 financial results and related highlights.
EXETER, N.H., May 9, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX: VAPO), (“Vapotherm” or the “Company”), today announced first quarter 2024 financial results and related highlights.
First Quarter 2024 Financial Results and Related Highlights
- Net revenue for the first quarter of 2024 was $19.1 million, an increase of 7.9% as compared to the first quarter of 2023
- Disposables revenue increased by 13.5% as compared to the first quarter of 2023
- Gross margin in the first quarter of 2024 was 50.5% as compared to 35.0% in the first quarter of 2023
- For the first quarter of 2024, GAAP operating expenses were $15.2 million and non-GAAP cash operating expenses, as defined below, were $13.2 million. Both decreased compared to the first quarter of 2023 as a result of the Company’s Path to Profitability initiatives:
- GAAP operating expenses decreased by $4.6 million from the first quarter of 2023
- Non-GAAP cash operating expenses decreased by $3.2 million from the first quarter of 2023
- Adjusted EBITDA loss in the first quarter of 2024 was $2.4 million as compared to an Adjusted EBITDA loss of $9.2 million in the first quarter of 2023
- The Company’s unrestricted cash and cash equivalents were $3.3 million at the end of the first quarter of 2024
“In the first quarter, we made significant progress on all of our key objectives,” said Joseph Army, President and CEO. “I’d like to thank the entire team for their efforts as we continue to drive further adoption of our technology and prepare for next year’s launch of our Access365 home ventilation solution, which was unveiled at MEDTRADE Dallas in March.”
Results for the Three Months Ended March 31, 2024
The following table reflects the Company’s net revenue for the three months ended March 31, 2024 and 2023:
| Three Months Ended March 31, | ||||||||||||||||||||||||
| 2024 | 2023 | Change | ||||||||||||||||||||||
| (in thousands, except percentages) | ||||||||||||||||||||||||
| Amount | % of Revenue | Amount | % of Revenue | $ | % | |||||||||||||||||||
| Revenue | ||||||||||||||||||||||||
| Capital (product & lease revenue) | $ | 3,547 | 18.5 | % | $ | 3,901 | 22.0 | % | $ | (354) | (9.1) | % | ||||||||||||
| Disposables | 14,096 | 73.7 | % | 12,417 | 70.0 | % | 1,679 | 13.5 | % | |||||||||||||||
| Service and other | 1,491 | 7.8 | % | 1,413 | 8.0 | % | 78 | 5.5 | % | |||||||||||||||
| Total net revenue | $ | 19,134 | 100.0 | % | $ | 17,731 | 100.0 | % | $ | 1,403 | 7.9 | % | ||||||||||||
Net revenue for the first quarter of 2024 was $19.1 million and increased 7.9% over the first quarter of 2023 primarily due to higher disposables sales in the United States.
Revenue information by geography is summarized as follows:
| Three Months Ended March 31, | ||||||||||||||||||||||||
| 2024 | 2023 | Change | ||||||||||||||||||||||
| (in thousands, except percentages) | ||||||||||||||||||||||||
| Amount | % of Revenue | Amount | % of Revenue | $ | % | |||||||||||||||||||
| United States | $ | 15,084 | 78.8 | % | $ | 13,014 | 73.4 | % | $ | 2,070 | 15.9 | % | ||||||||||||
| International | 4,050 | 21.2 | % | 4,717 | 26.6 | % | (667) | (14.1) | % | |||||||||||||||
| Total net revenue | $ | 19,134 | 100.0 | % | $ | 17,731 | 100.0 | % | $ | 1,403 | 7.9 | % | ||||||||||||
Gross profit and gross margin for the first quarter of 2024 was $9.7 million and 50.5%, respectively, as compared to gross profit of $6.2 million and gross margin of 35.0% for the first quarter of 2023. The increases in gross profit and gross margin were primarily due to improved efficiency of our Mexico operation.
Total operating expenses were $15.2 million in the first quarter of 2024, a decrease of $4.6 million as compared to the first quarter of 2023. Non-GAAP cash operating expenses, excluding impairment charges, gain (loss) on disposal of property and equipment, depreciation and amortization, stock-based compensation expense, termination benefits, and gain from deconsolidation were $13.2 million in the first quarter of 2024 compared to $16.4 million in the first quarter of 2023. The decreases in operating expenses and non-GAAP cash operating expenses were primarily due to the Company’s Path to Profitability initiatives.
Net loss for the first quarter of 2024 was $14.8 million, or $2.31 per share, compared to $18.1 million, or $3.56 per share, in the first quarter of 2023. Net loss per share was based on 6,430,502 and 5,076,075 weighted average shares outstanding for the first quarter of 2024 and 2023, respectively.
Adjusted EBITDA was negative $2.4 million for the first quarter of 2024 as compared to negative $9.2 million for the first quarter of 2023. The reduction in Adjusted EBITDA loss was primarily due to the Company’s Path to Profitability initiatives.
Cash Position
Unrestricted cash and cash equivalents were $3.3 million as of March 31, 2024 compared to $9.7 million as of December 31, 2023.
Website Information
Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/. Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherm’s disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherm’s website, in addition to following Vapotherm’s press releases, Securities and Exchange Commission (“SEC”) filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherm’s website is not incorporated by reference into, and is not a part of, this document.
Non-GAAP Financial Measures
This press release includes non-GAAP financial measures, including EBITDA, Adjusted EBITDA, non-GAAP operating expenses and non-GAAP cash operating expenses. EBITDA and Adjusted EBITDA differ from net income as calculated in accordance with U.S. generally accepted accounting principles (“GAAP”) and non-GAAP operating expenses and non-GAAP cash operating expenses differ from operating expenses as calculated in accordance with GAAP. EBITDA represents net loss less interest expense, net, income tax provision or benefit, and depreciation and amortization, and Adjusted EBITDA represents EBITDA as further adjusted for the impact of foreign currency (gain) loss, stock-based compensation expense, impairment of long-lived and intangible assets, gain from deconsolidation and gain (loss) on disposal of property and equipment. Non-GAAP operating expenses is calculated by excluding from GAAP operating expenses impairment of long-lived and intangible assets and gain (loss) on disposal of property and equipment, and non-GAAP cash operating expenses is calculated by further excluding additional items, including stock-based compensation, depreciation and amortization, and gain from deconsolidation The Company has reconciled all historical non-GAAP financial measures with the most directly comparable GAAP financial measures in tables accompanying this release.
These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these non-GAAP financial measures, as measures of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating budget and financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company believes Adjusted EBITDA is useful to its management and investors as a measure of comparative operating performance from period to period.
These non-GAAP financial measures should not be considered alternatives to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP. They should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our capital expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating Adjusted EBITDA, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in the Adjusted EBITDA presentation. The Company’s presentation of Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using Adjusted EBITDA and other non-GAAP financial measures on a supplemental basis. The Company’s definitions of Adjusted EBITDA, non-GAAP operating expenses and non-GAAP cash operating expenses are not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.
About Vapotherm
Vapotherm, Inc. (OTCQX: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 4.4 million patients have been treated with the use of Vapotherm high velocity therapy® systems. For more information, visit www.vapotherm.com.
Vapotherm high velocity therapy is mask-free non-invasive respiratory support and is a front-line tool for relieving respiratory distress—including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The HVT 2.0 and Precision Flow systems’ mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995, including statements about the future adoption of the Company’s HVT 2.0 system and preparing for the launch of its Access365 home ventilation solution. In some cases, you can identify forward-looking statements by terms such as “believe,” “expect,” “continue,” “plan,” “intend,” “will,” “outlook,” or “typically,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words, and the use of future dates. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include, but are not limited to the following: Vapotherm’s ability to raise additional capital to fund its existing operations and debt service obligations; Vapotherm’s ability to comply with its financial covenants, execute on its path to profitability initiative, convert excess inventory into cash and fund its business and otherwise continue as a going concern through 2024; Vapotherm’s has incurred losses in the past and may be unable to achieve or sustain profitability in the future; risks associated with its manufacturing operations in Mexico; Vapotherm’s dependence on sales generated from its High Velocity Therapy systems, competition from multi-national corporations who have significantly greater resources than Vapotherm and are more established in the respiratory market; the ability for High Velocity Therapy systems to gain increased market acceptance; Vapotherm’s inexperience directly marketing and selling its products; the potential loss of one or more suppliers and dependence on its new third party manufacturer; Vapotherm’s susceptibility to seasonal fluctuations; Vapotherm’s failure to comply with applicable United States and foreign regulatory requirements; the failure to obtain U.S. Food and Drug Administration or other regulatory authorization to market and sell future products or its inability to secure, maintain or enforce patent or other intellectual property protection for its products; the impact of COVID on its business, including its supply chain; risks in holding Vapotherm stock in light of trading on the OTCQX tier of the OTC Markets; and the other risks and uncertainties included under the heading “Risk Factors” in Vapotherm’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 22, 2024, and subsequent SEC reports. The forward-looking statements contained in this press release reflect Vapotherm’s views as of the date hereof, and Vapotherm does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
| Financial Statements: | ||||||||
| VAPOTHERM, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share amounts) | ||||||||
| March 31, 2024 | December 31, 2023 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 3,304 | $ | 9,725 | ||||
| Accounts receivable, net of expected credit losses | 10,203 | 10,672 | ||||||
| Inventories, net | 24,063 | 22,968 | ||||||
| Prepaid expenses and other current assets | 3,844 | 3,058 | ||||||
| Total current assets | 41,414 | 46,423 | ||||||
| Property and equipment, net | 23,313 | 23,703 | ||||||
| Operating lease right-of-use assets | 3,136 | 3,372 | ||||||
| Restricted cash | 1,109 | 1,109 | ||||||
| Goodwill | 560 | 565 | ||||||
| Deferred income tax assets | 55 | 57 | ||||||
| Other long-term assets | 2,320 | 2,388 | ||||||
| Total assets | $ | 71,907 | $ | 77,617 | ||||
| Liabilities and Stockholders’ Deficit | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 4,301 | $ | 5,053 | ||||
| Contract liabilities | 1,361 | 1,237 | ||||||
| Accrued expenses and other current liabilities | 20,531 | 12,805 | ||||||
| Current portion of loans payable, net | 111,670 | - | ||||||
| Total current liabilities | 137,863 | 19,095 | ||||||
| Long-term loans payable, net | - | 107,059 | ||||||
| Other long-term liabilities | 2,525 | 6,797 | ||||||
| Total liabilities | 140,388 | 132,951 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ deficit | ||||||||
| Preferred stock ($0.001 par value) 25,000,000 shares authorized; no shares | - | - | ||||||
| Common stock ($0.001 par value) 21,875,000 shares authorized as of | 6 | 6 | ||||||
| Additional paid-in capital | 494,615 | 492,764 | ||||||
| Accumulated other comprehensive (loss) income | (71) | 91 | ||||||
| Accumulated deficit | (563,031) | (548,195) | ||||||
| Total stockholders’ deficit | (68,481) | (55,334) | ||||||
| Total liabilities and stockholders’ deficit | $ | 71,907 | $ | 77,617 | ||||
| VAPOTHERM, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| (unaudited) | ||||||||
| Net revenue | $ | 19,134 | $ | 17,731 | ||||
| Cost of revenue | 9,477 | 11,519 | ||||||
| Gross profit | 9,657 | 6,212 | ||||||
| Operating expenses | ||||||||
| Research and development | 3,632 | 3,987 | ||||||
| Sales and marketing | 7,142 | 9,592 | ||||||
| General and administrative | 4,472 | 5,770 | ||||||
| Impairment of right-of-use assets | - | 432 | ||||||
| (Gain) loss on disposal of property and equipment | (8) | 55 | ||||||
| Total operating expenses | 15,238 | 19,836 | ||||||
| Loss from operations | (5,581) | (13,624) | ||||||
| Other (expense) income | ||||||||
| Interest expense | (9,253) | (4,331) | ||||||
| Interest income | 5 | 28 | ||||||
| Foreign currency gain (loss) | 4 | (154) | ||||||
| Net loss before income taxes | $ | (14,825) | $ | (18,081) | ||||
| Provision for income taxes | 11 | 9 | ||||||
| Net loss | $ | (14,836) | $ | (18,090) | ||||
| Other comprehensive income (loss): | ||||||||
| Foreign currency translation adjustments | (162) | 135 | ||||||
| Total other comprehensive (loss) income | (162) | 135 | ||||||
| Total comprehensive loss | $ | (14,998) | $ | (17,955) | ||||
| Net loss per share - basic and diluted | $ | (2.31) | $ | (3.56) | ||||
| Weighted-average number of shares used in calculating net | 6,430,502 | 5,076,075 | ||||||
| (1) On August 18, 2023, the Company effected a 1:8 reverse stock split for each share of common stock issued |
| VAPOTHERM, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (14,836) | $ | (18,090) | ||||
| Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
| Stock-based compensation expense | 1,834 | 2,820 | ||||||
| Depreciation and amortization | 1,306 | 1,248 | ||||||
| Provision for credit losses | 69 | 49 | ||||||
| Provision for inventory valuation | - | 165 | ||||||
| Non-cash lease expense | 235 | 387 | ||||||
| Impairment of right-of-use assets | - | 432 | ||||||
| (Gain) loss on disposal of property and equipment | (8) | 55 | ||||||
| Placed units reserve | 76 | 344 | ||||||
| Interest paid in-kind | 2,527 | 2,194 | ||||||
| Non-cash interest expense | 4,931 | 620 | ||||||
| Amortization of discount on debt | 184 | 184 | ||||||
| Deferred income taxes | 11 | 9 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 389 | 663 | ||||||
| Inventories | (1,112) | 4,384 | ||||||
| Prepaid expenses and other assets | (467) | (1,234) | ||||||
| Accounts payable | (561) | 114 | ||||||
| Contract liabilities | 124 | (25) | ||||||
| Accrued expenses and other current liabilities | (618) | (3,768) | ||||||
| Operating lease liabilities, current and long-term | (641) | (585) | ||||||
| Net cash used in operating activities | (6,557) | (10,034) | ||||||
| Cash flows from investing activities | ||||||||
| Purchases of property and equipment | (1,410) | (1,004) | ||||||
| Net cash used in investing activities | (1,410) | (1,004) | ||||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of common stock and pre-funded warrants and | - | 20,943 | ||||||
| Proceeds from loans, net of discount | 1,920 | - | ||||||
| Payment of deferred financing costs | (250) | - | ||||||
| Proceeds from exercise of stock options | 1 | - | ||||||
| Net cash provided by financing activities | 1,671 | 20,943 | ||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (125) | 70 | ||||||
| Net (decrease) increase in cash, cash equivalents and restricted cash | (6,421) | 9,975 | ||||||
| Cash, cash equivalents and restricted cash | ||||||||
| Beginning of period | 10,834 | 16,847 | ||||||
| End of period | $ | 4,413 | $ | 26,822 | ||||
| Supplemental disclosures of cash flow information | ||||||||
| Interest paid during the period | $ | 1,613 | $ | 1,284 | ||||
| Property and equipment purchases in accounts payable and accrued expenses | $ | 369 | $ | 354 | ||||
| Issuance of common stock warrants in conjunction with long term debt | $ | 16 | $ | 28 | ||||
| Issuance of common stock for services | $ | 20 | $ | 59 | ||||
Non-GAAP Financial Measures
The following table contains a reconciliation of net loss to Adjusted EBITDA for the three months ended March 31, 2024 and 2023, respectively.
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| (Unaudited) | (in thousands) | |||||||
| Net loss | $ | (14,836) | $ | (18,090) | ||||
| Interest expense, net | 9,248 | 4,303 | ||||||
| Provision for income taxes | 11 | 9 | ||||||
| Depreciation and amortization | 1,306 | 1,248 | ||||||
| EBITDA | $ | (4,271) | $ | (12,530) | ||||
| Stock-based compensation | 1,834 | 2,820 | ||||||
| Impairment of long-lived and intangible assets | - | 432 | ||||||
| Foreign currency (gain) loss | (4) | 154 | ||||||
| Gain from deconsolidation | - | (114) | ||||||
| (Gain) loss on disposal of property and equipment | (8) | 55 | ||||||
| Adjusted EBITDA | $ | (2,449) | $ | (9,183) | ||||
The following table contains a reconciliation of operating expenses to Non-GAAP operating expenses and Non-GAAP cash operating expenses for the three months ended March 31, 2024 and March 31, 2023, respectively.
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| (Unaudited) | (in thousands) | |||||||
| GAAP operating expenses | $ | 15,238 | $ | 19,836 | ||||
| Impairment of long-lived and intangible assets | - | (432) | ||||||
| Gain (loss) on disposal of property and equipment | 8 | (55) | ||||||
| Non-GAAP operating expenses | 15,246 | 19,349 | ||||||
| Stock-based compensation | (1,789) | (2,773) | ||||||
| Depreciation and amortization | (268) | (305) | ||||||
| Gain from deconsolidation | - | 114 | ||||||
| Non-GAAP cash operating expenses | $ | 13,189 | $ | 16,385 | ||||
| Supplemental Operating Metrics | |||||||||||||||
| March 31, | |||||||||||||||
| 2024 | 2023 | Change | |||||||||||||
| Amount | Amount | Amount | % | ||||||||||||
| HVT 2.0 and precision flow units installed base | |||||||||||||||
| United States | 24,802 | 24,488 | 314 | 1.3 | % | ||||||||||
| International | 13,126 | 12,586 | 540 | 4.3 | % | ||||||||||
| Total | 37,928 | 37,074 | 854 | 2.3 | % | ||||||||||
| Three Months Ended March 31, | |||||||||||||||
| 2024 | 2023 | Change | |||||||||||||
| Amount | Amount | Amount | % | ||||||||||||
| HVT 2.0 and precision flow units sold and leased | |||||||||||||||
| United States | 248 | 260 | (12) | (4.6) | % | ||||||||||
| International | 155 | 127 | 28 | 22.0 | % | ||||||||||
| Total | 403 | 387 | 16 | 4.1 | % | ||||||||||
| Disposable patient circuits sold | |||||||||||||||
| United States | 94,211 | 81,219 | 12,992 | 16.0 | % | ||||||||||
| International | 32,961 | 39,184 | (6,223) | (15.9) | % | ||||||||||
| Total | 127,172 | 120,403 | 6,769 | 5.6 | % | ||||||||||
Investor Relations Contacts:
John Landry, SVP & CFO, ir@vtherm.com, +1 (603) 658-0011
View original content to download multimedia:https://www.prnewswire.com/news-releases/vapotherm-reports-first-quarter-2024-financial-results-302141640.html
SOURCE Vapotherm, Inc.
Company Codes: OTC-BB:VAPO, OTC-PINK:VAPO, OTC-QX:VAPO, OtherOTC:VAPO
